Saturday 17 October 2026 Export LGND’s income statement to Excel — free account

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024. In the quarter to June 2026, revenue grew 33.7%, EPS grew 868.0% and free cash flow grew 35.5%, each against the same quarter a year earlier.

295.54 2.96 −0.99%

Follow LGND

Alert me

Market cap: $6.0B
P/E: 29.5×
Fwd P/E: 54.7×
Dividend yield: —
F-score: 6/9
Altman Z: 5.45
Beneish M: −4.02
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Ligand Pharmaceuticals Incorporated (LGND) P/E ratio

Alert me on P/E ratio

As of 16 October 2026, Ligand Pharmaceuticals Incorporated (LGND) trades at a P/E ratio of 29.5×. Over the past ten years it has ranged from 0.0× (September 2025) to 200× (September 2017); the current reading is higher than 61% of that period. That is above the Biotechnology industry median of 8.5× and above the Healthcare sector median of 23.0×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/LGND/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Ligand Pharmaceuticals Incorporated P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/LGND/metrics/pe-ratio">Ligand Pharmaceuticals Incorporated (LGND) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	30.0×	—
FY2024	0.0×	—
FY2023	23.8×	—
FY2022	0.0×	—
FY2021	27.8×	—
FY2020	0.0×	—
FY2019	2.1×	(83.05%)
FY2018	12.5×	(91.30%)
FY2017	144×	—
FY2016	0.0×	—

Period	P/E ratio	Change
Jun 2026	31.6×	24.00%
Mar 2026	25.5×	(15.15%)
Dec 2025	30.0×	(59.51%)
Sep 2025	74.1×	—
42 more quarters	Free account

Against its own ten years

Low 0.0× High 200×

Ten-year median 20.5×

Current reading's percentile 51

Company	P/E ratio
KOD Kodiak Sciences Inc. compare	n/m
ERAS Erasca, Inc. compare	n/m
MIRM Mirum Pharmaceuticals, Inc. compare	n/m
CGON CG Oncology, Inc. compare	n/m
IMVT Immunovant, Inc. compare	n/m
IOVA Iovance Biotherapeutics, Inc. compare	n/m
RYTM Rhythm Pharmaceuticals, Inc. compare	n/m
BLTE Belite Bio, Inc. Sponsored ADR compare	n/m
LGND Ligand Pharmaceuticals Incorporated	29.5×
Biotechnology industry median	8.5×
Healthcare sector median	23.0×
Market median	18.1×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Ligand Pharmaceuticals Incorporated (LGND) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on LGND

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on LGND

Stockrow Weekly